A study to look at a new medicine called, “GDC-0134”, for treating patients with amyotrophic lateral sclerosis (ALS)

A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis

Neurodegenerative Disorder
Amyotrophic Lateral Sclerosis

Results
Download

Study results

LPS GN29823 Final Results Jaunary 2021 Netherlands Dutch (PDF, 0.2 MB)

LPS GN29823 Final Results Jaunary 2021 English (PDF, 0.2 MB)

LPS GN29823 Final Results Jaunary 2021 Canada French (PDF, 0.2 MB)

LPS GN29823 Final Results Jaunary 2021 USA Spanish (PDF, 0.2 MB)

What is Clinical Research?

In clinical research, volunteers, researchers, and medical professionals work together toward a shared goal: better treatment outcomes for patients. Clinical trials are vital to their process. They are carefully designed and follow approved protocols.

A study to look at a new medicine called, “GDC-0134”, for treating patients with amyotrophic lateral sclerosis (ALS)

Study results

LPS GN29823 Final Results Jaunary 2021 Netherlands Dutch (PDF, 0.2 MB)

LPS GN29823 Final Results Jaunary 2021 English (PDF, 0.2 MB)

LPS GN29823 Final Results Jaunary 2021 Canada French (PDF, 0.2 MB)

LPS GN29823 Final Results Jaunary 2021 USA Spanish (PDF, 0.2 MB)

What is Clinical Research?

For the latest version of this information please go to www.forpatients.roche.com

External Site

Directly contact Roche for questions

Contact the hospital directly

You are about to leave ForPatients

Thank you

Request a call back

Find participating medical centers and current study status in each of them

A study to look at a new medicine called, “GDC-0134”, for treating patients with amyotrophic lateral sclerosis (ALS)

For the latest version of this information please go to www.forpatients.roche.com